This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: S&t Biomed Co., Ltd.. Active years: 2021.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2021
Title: Innovations in Cancer Diagnosis by Lai-Chu See
Introduction
Lai-Chu See is a notable inventor based in Taoyuan, Taiwan. He has made significant contributions to the field of cancer diagnosis and prognosis. His innovative methods aim to improve early detection and treatment options for patients at risk of developing cancer.
Latest Patents
Lai-Chu See holds a patent for a method of cancer diagnosis and prognosis. This method involves obtaining a sample from a subject and determining the levels of at least two target polypeptides, which include ANXA2, HSPA5, KNG1, and MMP1. By assessing these levels, the method can indicate whether a subject has or is at risk of developing cancer. This approach provides a potential means to diagnose and predict the occurrence of oral squamous cell carcinoma, allowing for timely therapeutic interventions.
Career Highlights
Lai-Chu See is associated with S&T Biomed Co., Ltd., where he continues to work on innovative solutions in the biomedical field. His expertise in cancer research has positioned him as a valuable contributor to advancements in medical diagnostics.
Collaborations
Lai-Chu See collaborates with talented individuals such as Jau-Song Yu and Yi-Ting Chen. Their combined efforts enhance the research and development of effective cancer diagnostic methods.
Conclusion
Lai-Chu See's work in cancer diagnosis exemplifies the impact of innovative thinking in the medical field. His contributions are paving the way for improved patient outcomes through early detection and intervention.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile